Today, approximately 50% of Genentech’s pipeline and marketed products derive from successful collaborations with companies and institutions from around the world.
We’re known for exceptional science and pioneering medical breakthroughs. We bring that same innovative and entrepreneurial spirit to our partnerships.
At Genentech, we’re committed to building collaborations that create the most value for each partner.
We’re flexible. Our business development team custom designs collaborations to meet each partner’s needs. Deal structures range from traditional milestone and royalty deals to acquisitions and options. We often fund collaborative research.
We welcome opportunities in the following areas:
- Cardiovascular Disease
- Infectious Disease
- Metabolic Disease
- Ophthalmic Disease
- Biomarker Assay Technologies
- Therapeutic Lead Discovery Technologies
It is important for both partners to have a productive business relationship as well as complimentary scientific contributions. We typically provide an alliance manager as your main contact for business and relationship matters once the collaboration begins. This helps both teams stay focused on advancing science and delivering benefit to patients.
How the alliance manager benefits our partnerships:
- Serves as a responsive resource to address business-related matters
- Efficiently manages basic business operations
- Anticipates needs in support of major decisions and events
- Engages with governance committees for strategic alignment
- Ensures a smooth transition to Roche's global development organization following Phase II proof-of-concept
Collaborate with Us
If you would like to partner with Genentech, please provide a detailed non-confidential package that describes the opportunity, including scientific supporting data, such as mechanism of action for therapeutics.
Send your proposals to:
1 DNA Way, MS 53
South San Francisco, California 94080
Our Relationship with Roche
Genentech and Roche maintain independent R&D organizations served by separate business development groups. Genentech Partnering supports the Genentech Research and Early Development group, responsible for developing drug candidates from discovery through Phase II proof-of-concept in humans. View our pipeline.
With a separate budget and independent decision-making, we pursue our own R& collaborations with companies and academic institutions from all over the world. Then we leverage the Roche global infrastructure for late-stage development, manufacturing and commercialization.